Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.
The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.